13F-HR filed by Decheng Capital LLC
Decheng Capital LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-12, with 19 holding rows worth $743,406,873.
- Accession
- 0001104659-26-014146
- Filer
- CIK 2010850
- Filed
- 2026-02-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 19 entries on the cover page, a total value of $743,406,873 stated on the cover page (in dollars after the unit check, H1), rows summing to $743,406,873 with VALUE read as dollars as filed, 13F file number 028-23697. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 6,371,669 | $264,551,697 | dollars as filed | |
| NUVATION BIO INC COM CL A | 67080N101 | Stock | 25,954,439 | $232,551,773 | dollars as filed | |
| UPSTREAM BIO INC | 91678A107 | COMMON STOCK | 3,143,078 | $85,334,568 | dollars as filed | |
| AARDVARK THERAPEUTICS INC | 002942100 | COM | 3,917,299 | $51,414,550 | dollars as filed | |
| LYELL IMMUNOPHARMA INC | 55083R104 | COM | 692,050 | $21,301,299 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 592,057 | $20,769,360 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 200,000 | $15,930,000 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 541,559 | $12,905,351 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 4,041,736 | $12,165,625 | dollars as filed | |
| EQUILLIUM INC | 29446K106 | COM | 4,447,308 | $6,893,328 | dollars as filed | |
| BEYONDSPRING INC | G10830100 | SHS | 3,800,702 | $6,195,145 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 92,700 | $4,315,185 | dollars as filed | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 17,300 | $4,265,142 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 360,483 | $1,964,632 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 1,323,327 | $1,786,491 | dollars as filed | |
| PYXIS ONCOLOGY INC COMMON STOCK | 747324101 | Stock | 326,810 | $375,832 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 44,311 | $332,333 | dollars as filed | |
| NUVATION BIO INC | 67080N119 | WARR | 646,057 | $213,198 | dollars as filed | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 59,900 | $141,364 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-26-014146 | this filing | 2026-02-12 | acceptance time not in the bulk data set |